# BEAM — slm-full-gpu

## Metadata

ticker: BEAM
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: c819344de0a30b7c8394d80c97946372b1595d5fd07434c9544c0a76c7c8cd07
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 752, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 21.517, "latency_s_total": 21.517, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 475, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 15.27, "latency_s_total": 15.27, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 150, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.721, "latency_s_total": 7.721, "parse_failure": 0, "prompt_tokens": 678, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 167, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.282, "latency_s_total": 9.282, "parse_failure": 0, "prompt_tokens": 672, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 172, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.711, "latency_s_total": 9.711, "parse_failure": 0, "prompt_tokens": 547, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 163, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.259, "latency_s_total": 9.259, "parse_failure": 0, "prompt_tokens": 832, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 937, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 13.214, "latency_s_total": 13.214, "parse_failure": 0, "prompt_tokens": 1682, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 25.67,
  "currency": "USD",
  "market_cap": 2651394304.0,
  "forward_pe": -5.414047,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "financial_currency": "USD",
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin_pct": -55.45,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the Annual Report on Form 10-K for BEAM, the key takeaways regarding the company's financial position, operational status, and future outlook are as follows:

**Financial Performance and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** BEAM expects to incur significant expenses and increasing operating losses for the foreseeable future. The company requires substantial additional funding to support research and development, clinical trials, and potential commercialization efforts.
*   **Liquidity Position:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities. Management believes this amount is sufficient to fund operating expenses and capital expenditures for at least the next 12 months, though this may change due to unknown factors.
*   **No Committed Capital:** Aside from a credit facility with Sixth Street Lending Partners, the company has no committed external source of additional capital. Failure to raise capital on acceptable terms could force the company to delay, reduce, or eliminate research programs or commercialization efforts.

**Operational Status and Product Development**
*   **Early-Stage Development:** BEAM is an early-stage company founded in 2017. It has not yet completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines.
*   **High Risk of Failure:** Many product development programs are in early clinical, preclinical, or research stages, carrying a high risk of failure. The company has not demonstrated the ability to successfully complete pivotal trials, manufacture commercial-scale medicines, or conduct sales and marketing activities.
*   **Past Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which included cost-reduction initiatives that resulted in the pausing or elimination of certain pipeline programs.

**Risks Related to Dilution and Agreements**
*   **Stockholder Dilution:** Raising additional capital through equity or convertible debt offerings will dilute existing stockholders. Future issuances of shares to partners and collaborators for milestone payments may also cause substantial dilution.
*   **Restrictive Covenants:** The financing agreement with Sixth Street Lending Partners includes covenants that restrict actions such as incurring additional debt, making capital expenditures, and declaring dividends.
*   **License and Collaboration Risks:** The company may be forced to seek collaborators at earlier stages than desirable or on less favorable terms. Failure to meet payment obligations under license or collaboration agreements could lead to their termination. Additionally, the company faces potential success liabilities to Harvard and the Broad Institute.

**Long-Term Viability**
*   **Uncertain Path to Profitability:** The company may never achieve or maintain profitability. Even if profitable, it may not be able to sustain or increase profitability on a quarterly or annual basis.
*   **Short Operating History:** With a short history in a rapidly evolving field, it is difficult to evaluate the company's success or predict its future viability. Typical medicine development takes 10 to 15 years, and BEAM has not yet shown it can navigate this timeline successfully.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to incur significant expenses and increasing operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Additional Funding:** Substantial additional funding is required to continue operations, expand clinical trials, and seek marketing approvals. If capital cannot be raised when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research and product development programs or commercialization efforts.
*   **Lack of Commercial History and Product Approval:** The company has not completed any pivotal clinical trials, obtained marketing approvals, manufactured a commercial-scale medicine, or established sales and marketing infrastructure. It typically takes 10 to 15 years to develop a new medicine, and the company may never have a product candidate approved for commercialization.
*   **Limited Operating History:** The company has a short operating history in the rapidly evolving base editing and gene editing fields, making it difficult to evaluate its technology, industry, or predict future performance.
*   **Execution Risks:** The company faces risks associated with identifying product candidates, completing preclinical studies and clinical trials, obtaining regulatory approval, manufacturing, and commercializing medicines. Failure to succeed in these activities could impair the company’s ability to raise capital, maintain R&D efforts, or continue operations.
*   **Past Strategic Changes:** The company has previously delayed, reduced, or eliminated research and product development programs to decrease operating expenses, such as through the portfolio reprioritization and strategic restructuring announced in October 2023.
*   **License and Collaboration Risks:** Current and future license and collaboration agreements may be terminated if the company is unable to meet payment or other obligations. Additionally, the company faces contingent liabilities and costs related to acquiring licenses, maintaining intellectual property, and potential payments to Harvard and the Broad Institute.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $25.67 with a market capitalization of approximately $2.65 billion. The company reported revenue of $156.04 million, but faces significant profitability challenges with a net loss of $86.52 million, resulting in a negative profit margin of -55.45%. Consequently, the forward P/E ratio is negative at -5.41, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk, pre-profitability stage typical of biotechnology firms heavily invested in R&D. Investors should monitor future revenue growth and cash burn rates closely as key indicators of long-term viability.

### Recent Developments

Beam Therapeutics Inc. recently filed its Annual Report on Form 10-K on February 24, 2026, and its Quarterly Report on Form 10-Q on August 4, 2026, both of which highlight significant risk factors that could materially impact the company's financial condition. These regulatory filings underscore the ongoing uncertainties and potential challenges facing the biotechnology firm, particularly regarding its operational and financial stability. Investors should closely monitor these disclosed risks, as they may lead to increased volatility in the stock price, which currently trades near its 52-week low of $20.23. With the company reporting a negative net income and a negative forward P/E ratio, the emphasis on risk factors in recent filings suggests a cautious outlook for near-term performance.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it continues to operate at a loss while funding early-stage development. The company holds $1.2 billion in cash and marketable securities, which management believes is sufficient to cover operating expenses and capital expenditures for at least the next 12 months. Despite this liquidity position, BEAM remains an early-stage entity with no commercialized products or completed pivotal trials, facing significant risks related to product development failure and future capital needs. The firm lacks committed external capital sources beyond a credit facility with Sixth Street Lending Partners, meaning any future equity raises could substantially dilute existing stockholders.

### Risk Factors

*   **Substantial Financial Losses and Capital Requirements:** The company has incurred significant operating losses (accumulated deficit of $1.6 billion as of Dec 2025) and requires substantial additional funding to continue operations and clinical trials; failure to raise capital on attractive terms could force delays or elimination of development programs.
*   **Pre-Commercial Stage and Regulatory Uncertainty:** BEAM has no commercial history, has not completed pivotal trials, and lacks marketing approvals or commercial-scale manufacturing infrastructure, meaning it may never achieve product commercialization or profitability.
*   **Execution and Strategic Risks:** The company faces challenges in a rapidly evolving field with a short operating history, including risks related to clinical trial success, regulatory approval, and past strategic restructuring that has already led to the reduction or elimination of certain product candidates.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. is a pre-commercial biotechnology firm specializing in base editing, currently navigating a high-risk phase characterized by an accumulated deficit of $1.6 billion and no commercialized products. The stock is notable for its proximity to the 52-week low of $20.23 and its reliance on a $1.2 billion cash runway to sustain operations through early-stage development. The single most important near-term variable is the successful execution of clinical trials and the ability to secure external capital without excessive dilution, given the lack of committed funding sources beyond existing facilities.

### Outlook
The directional outlook for Beam Therapeutics remains cautious, reflecting the inherent binary risks of a pre-commercial biotech firm with no approved products or pivotal trial data. While the company possesses a substantial cash reserve that provides a near-term buffer against immediate insolvency, the absence of committed external capital sources and the history of strategic restructuring create significant headwinds regarding long-term viability. Investors should monitor clinical trial progress and the company’s ability to manage cash burn as primary variables; positive data readouts or successful partnerships could strengthen the thesis, whereas trial delays or adverse safety signals would likely weaken investor confidence and increase the probability of dilutive capital raises.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "As of December 31, 2025, the accumulated deficit stood at $1.6 billion," and the Pre-Written SEC Filing Highlights section repeats this figure.

---

CLAIM: "no commercialized products"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states BEAM "has not yet completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines," and the Pre-Written SEC Filing Highlights confirms "no commercialized products or completed pivotal trials."

---

CLAIM: "52-week low of $20.23"
LABEL: SUPPORTED
REASON: The raw stock data explicitly lists "week_52_low": 20.23, and the Pre-Written Recent Developments section also cites this figure.

---

CLAIM: "$1.2 billion cash runway"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities," confirmed in the Pre-Written SEC Filing Highlights section.

---

CLAIM: "lack of committed funding sources beyond existing facilities"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights states "Aside from a credit facility with Sixth Street Lending Partners, the company has no committed external source of additional capital," which directly supports this characterization.

---

**OUTLOOK**

---

CLAIM: "no approved products"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both confirm BEAM has not "obtained marketing approvals" for any product.

---

CLAIM: "no … pivotal trial data"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states the company has "not yet completed any pivotal clinical trials," confirmed across multiple pre-written sections.

---

CLAIM: "absence of committed external capital sources"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights states "the company has no committed external source of additional capital" beyond the Sixth Street credit facility, directly supporting this claim.

---

CLAIM: "history of strategic restructuring"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and Risk Factors sections reference the "portfolio reprioritization and strategic restructuring announced in October 2023," which included pausing or eliminating certain pipeline programs.

---

**NO ADDITIONAL QUANTITATIVE OR FORWARD-LOOKING CLAIMS IDENTIFIED**

The Outlook section contains no additional specific quantitative figures, price targets, thresholds, ratios, percentages, named product milestones, or forward-looking numbers beyond those already evaluated above. All directional statements (e.g., "positive data readouts," "trial delays," "dilutive capital raises") are qualitative and do not constitute auditable quantitative claims under the defined scope.
